EXPERT VIDEOCURBSIDE CONSULTSCME
Utilizing PCSK9 Inhibitors: Who? When? How Long?
|Author(s)/Faculty: Robert P. Giugliano, MD, SM, FACC, FAHA; Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA|
|Release Date: 11/21/2016||Expiration Date: 11/20/2017|
|Credit Type: CME||Number of Credits: 0|
|Content Type: Video||Provider: |
|Elevated LDL-C levels contribute to enhanced cardiovascular risk. Despite reducing the risk of cardiovascular disease, residual risk remains in patients taking statins. This CME activity will discuss the use of PCSK9 inhibitors in patients with elevated LDL-C levels who are at risk for cardiovascular disease, despite statin therapy.|